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ABSTRACT
Despite optimal supportive care and high-resolution HLA matching, complications such as GVHD and
infection remain major barriers to the success of allogeneic HCT (allo-HCT). This has led to growing interest
in the non-HLA genetic determinants of complications after allo-HCT. Most studies have examined genetic
predictors of GVHD, relapse, and mortality and have focused on 3 main areas: minor histocompatibility antigen
(miHAs), inflammatory mediators of GVHD, and more recently NK cell-mediated allorecognition. The
genetic basis of other outcomes such as infection and drug toxicity are less well studied but are being actively
investigated. High-throughput methodologies such as single nucleotide polymorphism arrays are enabling the
study of hundreds of thousands of genetic markers throughout the genome and the interrogation of novel
genetic variants such as copy number variations. These data offer the opportunity to better predict those at risk
of complications and to identify novel targets for therapeutic intervention. This review examines the current
data regarding the non-HLA genomics of allo-HCT and appraises the promises and pitfalls for integration of
this new genetic information into clinical transplantation practice.
© 2007 American Society for Blood and Marrow Transplantation
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cPECTRUM OF COMPLICATIONS OF ALLOGENEIC HCT
Allogeneic HCT (allo-HCT) is widely used to
reat a diverse range of malignant and nonmalignant
iseases. The growing indications for allo-HCT and
he development of reduced intensity conditioning
egimens has seen the number of allogeneic transplan-
ations continue to increase, with 15 000 performed
orldwide in 2002 [1]. However, transplant-related
omplications remain a major obstacle [2]. The 100-d
ortality rate for standard-risk patients receiving a
ransplant from an HLA-identical sibling is
5%-20%. Mortality is higher for patients who are
lder, those with signiﬁcant comorbidity, those un-
ergoing transplantation for other indications, and
hose receiving unrelated donor transplants. Disease
elapse is the leading cause of death (30%-34% of
eaths after HLA-identical sibling transplantations)
1,2], but transplant-related complications are also im-
ortant. These include GVHD (15%-25%), major
nfection (10%-17%), and other treatment-related toxicities (35% of deaths) such as interstitial pneumo-
itis and hepatic veno-occlusive disease. Long-term
auses of morbidity include cGVHD and infection.
hese complications remain signiﬁcant in transplan-
ations using reduced intensity conditioning regimens
3].
Prevention of these complications has tradition-
lly relied on meticulous supportive care, prophylactic
ntimicrobials and immunosuppression, and accurate
atching of donors and recipients for HLA alleles.
LA matching to minimize graft rejection and the
eading cause of transplant-related morbidity,
VHD, remains a cornerstone of modern transplan-
ation management [4]. GVHD arises from the rec-
gnition of recipient tissues as foreign by donor T
ells. Three key requirements for the development of
VHD were described by Billingham in 1966 [5].
hese are the presence of immunologically competent
ells in the graft, the inability of the recipient to reject
he transplanted cells, and the presence of antigens,
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C. G. Mullighan and P. G. Bardy128LA antigens, in the recipient that are lacking in the
raft. However, despite optimal HLA matching using
igh-resolution molecular techniques, aGVHD re-
ains a major problem [6]. More than 30% of patients
ith chronic myeloid leukemia receiving an HLA-
atched unrelated donor transplant develop severe
grades III-IV) acute GVHD [7].
If HLA disparity is central to the development of
VHD, why doesn’t HLA matching prevent it? It is
ow appreciated that the initiation and propagation
f GVHD is a multifactorial, multistep process that
ncludes, but is not restricted to, classic HLA al-
orecognition [8]. GVHD is critically dependent on
dditional pathways including non-classic HLA al-
orecognition (such as by NK cells), allorecognition
f miHAs, and an inﬂammatory milieu. The relative
mportance of each of these pathways is context de-
endent and is inﬂuenced by recipient characteristics,
onor type, stem cell source, intensity of condition-
ng, and degree of HLA matching. Importantly, the
ediators of these pathways are encoded by highly
olymorphic immunoregulatory genes, and there are
onsiderable data implicating such “non-HLA” im-
unogenetic polymorphisms in the risk and severity
f GVHD. Further, the pathophysiology and genetic
eterminants inﬂuencing risk of other complications
ay be distinct from GVHD and less dependent on
LA.
Consequently, there has been intense interest in
eﬁning the best non-HLA genetic markers of allo-
CT outcomes and incorporating these into routine
issue typing strategies. However, the profusion of
enetic markers poses formidable challenges to the
evelopment of robust predictive models. This review
xamines the evidence for non-HLA genetic risk fac-
ors in allo-HCT, highlights problems raised by ex-
sting studies, and discusses potential strategies to
vercome these issues. In addition, newer high-
hroughput approaches to identify genetic risk factors
re discussed.
The continuing centrality of HLA matching in
llo-HCT cannot be overemphasized, and optimal
LA typing approaches continue to evolve. In partic-
lar, high-resolution HLA typing approaches may re-
uce the number of fully HLA-matched unrelated
onors. Recent elegant studies have begun to address
ssues of permissible HLA mismatches and tradeoffs
ith other factors such as time to transplantation
9,10]. A full discussion of these issues is beyond the
cope of this review, and the reader is referred else-
here [6,11].
INOR HISTOCOMPATIBILITY ANTIGENS AND
LLO-HCT OUTCOME
The miHAs are of interest in allo-HSCT as risk
actors for allo-HCT outcome and as potential targets oor immunotherapy [12-15]. The miHAs are short
eptides, frequently derived from intracellular pro-
essing of proteins, that are presented on host HLA
olecules and can stimulate alloreactive T cell im-
une responses between HLA-matched individuals.
he tissue distribution of miHAs is variable, with
ome (eg, HA-1) expressed only by cells of hemato-
oietic origin, and others being ubiquitously ex-
ressed. Some miHAs are expressed by hematopoietic
umors, such as proteinase 3 in CML, and are thus
otential targets of graft-versus-leukemia (GVL) re-
ponses. The genes encoding miHAs are frequently
olymorphic, resulting in variation in peptide se-
uence that can inﬂuence intracellular processing or
resentation of miHA peptide, and the stimulation of
n alloreactive response if donors and recipients are
isparate (mismatched) for miHA genotype.
miHA gene polymorphism may result in missense
hanges in the miHA peptide presented by HLA and
n potential disparity in miHA genotype between do-
or and recipient. miHA peptides are usually only
resented by a single HLA allele; eg, HA-1 is pre-
ented by HLA-A*0201. Hence, HA-1 mismatching is
nly relevant to the subset of transplants whose do-
ors and recipients are HLA-A*0201 positive.
The most extensively studied miHA is HA-1, a
onapeptide encoded by the HMHA1 (HA-1 or
IAA0223) gene with 2 alleles deﬁned by histidine
HA-1H) or arginine (HA-1R) at the third amino acid
f the peptide. Because the HA-1H peptide binds with
uch greater afﬁnity to HLA-*0201 than the HA-1R
llele, transplants from HA-1R/R donors to HA-1H
ositive recipients can potentially cause GVHD, but
ot the reverse [16]. Numerous groups have examined
A-1 disparity as a risk factor for GVHD (Table 1).
oulmy et al [17] detected a signiﬁcant association
etween HA-1 disparity and aGVHD in sibling my-
loablative transplants, suggesting that HA-1 disparity
ould be used clinically as a predictor of GVHD.
ubsequent studies have been conﬂicting, and the
argest studies have concluded that the effect of HA-1
isparity is, at best, weak [18-25]. Conﬂicting results
ave also been reported for polymorphisms in the
ECAM1 gene (CD31) and allo-HCT outcome
20,23-30] (Table 1). Many of the studies are small
nd clinically heterogenous, and it is difﬁcult to be
onclusive about the role of miHA genetic polymor-
hism as a predictor of transplantation outcome. As
iscussed below, further studies will need to examine
he role of miHA variants simultaneously with other
mmunogenetic and clinical variables.
Interest in miHAs as potential therapeutic targets
or graft-versus-tumor responses has been driven by
he observations that miHA expression is often limited
o hematopoietic tumor cells [31-33], and that expan-
ion of miHA-speciﬁc CTLs accompanies attainment
f full donor lymphoid chimerism and disease remis-
Table 1. Associations between miHAs and Allo-HSCT Outcome
Study Donor, n miHA Studied Associated Genetic Variant Associations
Goulmy et al [17] Sibling, 148 HA-1, 2, 4, 5, HY HA-1 mismatch
>1 mismatch in HA-1,-2,
4, or 5
1 aGVHD II-IV
1 aGVHD II-IV
Behar et al [26] Sibling, 46 CD31 codon 125 CD31 mismatch 1 aGVHD
Nichols et al [27] Sibling, 301 CD31 codon 125 No association with aGVHD
Da Costa et al [174] Sibling, 96 URD, 4 CD31 codon 125 No association with aGVHD
Maruya et al [28] Sibling, 118 CD2, CD31, CD42, CD49b, CD54, CD62L CD31 codons
CD62LCD49b CD31
1 aGVHD
1 aGVHD
Balduini et al [20] Paediatric REL 37, URD 70 HPA-1, 2, 3, 5, CD31 (codon 125) codon 125
HPA-3
1 aGVHD II-IV
1 aGVHD
Juji et al [175] URD, 715 HPA 2-6 HPA-5 mismatching 2 Survival
Tseng et al [18] Sibling, 237 HA-1 HA-1 disparity Trend to 1 aGVHD
Lin et al [19] Sibling, 613 HA-1 No associations with aGVHD, cGVHD,
survival
Grumet et al [179] Sibling, 118 CD31 codons 125, 563, 670 Codon 563/670* mismatch
Codon 125 mismatch
2 Survival 1 aGVHD III-IV
2 Survival 1 aGVHD III-IV
Balduini et al [20] Sibling, 92 URD 58 HA-1, H-Y CD31 codons 125 and 563 CD31 codon 563 D/R mismatch 1 aGVHD II-IV
Gallardo et al [180] Sibling, 215 HA-1 HA-1 mismatch 1 aGVHD II-IV,
Tait et al [22] Sibling, 129 HA-1 No association with aGVHD
Socie et al [74] Sibling, 100 HA-1 HA-1 mismatch 1 aGVHD, RR 2.8
Rocha et al [23] Sibling, 107 CD31 No association with aGVHD
Kogler et al [24] UCB, 115 HY, HA-1, CD31 codon 125 No associations with aGVHD II-IV
Akatsuka et al [176] Sibling, 577 HA-8 (KIAA0020) HA-8 D/R disparity 1 aGVHD II-IV
Nesci et al [177] Sibling, thalassemic, 94 HA-1 No association with aGVHD
Rozman et al [110] Sibling, 223 HPA-1, 2, 3, 4, 5 No associations with GHVD or
survival
Heinemann et al [25] Sibling, 94 URD, 69 HA-1, CD31, CD49b No independent associations
Nishida et al [178] URD, 320 ACC-1 ACC-1 disparity No associations with aGHVD, cGVHD,
relapse, DFS
Cavanagh et al [29] Sibling, 74 CD31 V/N/G haplotype (D)
Codon 563 heterozygosity (D)
1 aGVHD
2OS
Perez-Garcia et al
[21]
Sibling, 146 HA-8 HA-8 D/R disparity 1 aGVHD III-IV, 2DFS, 2OS
Katagiri et al [30] Sibling 60, URD46 HA-1, CD31 codons 125, 563, CD49b, CD62L CD62L and CD31
incompatibility
2 Relapse
HPA indicates human platelet alloantigen; OS, overall survival; REL, related (donor transplant); UCB, unrelated cord blood; URD, unrelated donor; D, donor; R, recipient;1, increased;2, decreased.
*Identical associations seen for codons 563 and 670.
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C. G. Mullighan and P. G. Bardy130ion [13,34,35]. miHA-speciﬁc donor T cells have
een shown to mediate GVH reactions ex vivo using a
kin explant model [35]; conversely, murine experi-
ental systems demonstrating the capability of
iHA-speciﬁc CTLs to mediate GVL effects without
VHD have been described [36]. Strategies to expand
iHA-speciﬁc T cells ex vivo to enhance antitumor
esponses without increasing GVHD are conse-
uently being actively explored. These complex ap-
roaches are presently restricted to a small number of
enters but are likely to become more widely used.
HE MULTISTEP PATHOGENESIS OF GVHD
It is now well established that the pathogenesis of
GVHD is critically dependent on a number of in-
ammatory pathways in addition to classic T cell/
LA allorecognition. Activation of these pathways
ccurs before infusion of donor T cells and may result
rom underlying disease and prior treatment, even
efore administration of conditioning regimens. Many
nﬂammatory mediators of these pathways, including
ytokines, chemokines, and adhesion molecules, are
igure 1. The 3-stage pathogenesis of aGVHD. In stage 1, con
ranslocates from the intestinal lumen to the circulation, resulting in
f MHC antigens and adhesion molecules on host tissues, which in t
n stage 2, TH1 T cells proliferate in the presence of IL-12 and secr
TL and NK cell responses, and activate mononuclear phagocytes
NF. In phase 3, effector functions of activated mononuclear pha
hrough the intestinal mucosa damaged during phases 1 and 2. This
ut damage ampliﬁes LPS release and leads to the “cytokine stormncoded by polymorphic genes, and there is now com- velling evidence that these polymorphisms inﬂuence
llo-HCT outcome. Before examining these data, it is
mportant to review this model of GVHD pathogen-
sis.
The development of GVHD may be divided into
interrelated stages (Figure 1) [8]. In the ﬁrst stage,
he conditioning regimen, prior disease, and comor-
idity result in liberation of proinﬂammatory cyto-
ines such as TNF and IL-1 [37]. This proinﬂamma-
ory milieu upregulates expression of HLA and
ostimulatory molecules on APCs, which facilitates an
lloimmune response. Microbial mediators cross dam-
ged gut mucosa, further amplifying this systemic in-
ammatory response [37-39]. The importance of this
cytokine storm” [40] is supported by extensive evi-
ence from mouse models of GVHD [37,41-44] and
linical allo-HCT data showing that increases in cir-
ulating levels of cytokines such as TNF, IL-2, IL-6,
L-8, IL-12, and IFN-, and polymorphisms in cyto-
ine genes predict the occurrence and severity of
GVHD [45-63]. The role of pro- and anti-inﬂam-
atory cytokines in the development of GVHD is
omplex and is likely dependent on transplantation
ing causes damage and activation of host tissues. Bacterial LPS
tion of inﬂammatory cytokine secretion and upregulated expression
ance the recognition of MHC and miHAs by mature donor T cells.
2 and IFN-. IL-2 and IFN- induce further T cell expansion and
and NK effectors damage tissue by perforin/granzyme, FasL, and
s are triggered by LPS and other stimulatory molecules that leak
es local tissue injury and further drives an inﬂammatory response.
GVHD. Reproduced with permission from Hill and Ferrara [39].dition
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Genomics of Allogeneic Stem Cell Transplantation 131ource and dose, GVHD prophylaxis, and site of
VHD [64,65]. In a recent study examining levels of
0 pro- and anti-inﬂammatory cytokines in 113 non-
yeloablative transplants, an increase in the level of
L-12, but no other cytokines, accompanied the de-
elopment of aGVHD [66]. IL-12 drives the expan-
ion of TH1 T lymphocytes, which was also observed
n patients demonstrating GVHD. The striking asso-
iation of GVHD with levels of IL-12, but none of the
ther inﬂammatory cytokines commonly associated
ith GVHD in myeloablative allo-HCT, suggests the
athogenesis and role of cytokine dysregulation differs
etween the 2 transplant settings. This has important
mplications for the design of non-HLA genomic
tudies, as discussed below.
The second stage of GVHD involves presentation
f recipient antigen on MHC molecules by APCs to
onor T cells, followed by activation, proliferation,
nd secretion of cytokines such as IL-2 and IFN- by
hese cells. These cytokines activate cytotoxic T cells
nd NK cells, prime macrophages to release TNF,
esulting in further inﬂammation, and induce skin and
ut GVHD pathology. In the ﬁnal, effector phase of
VHD, soluble and cellular effectors mediate recip-
ent tissue damage. These include cytokines such as
NF and IL-1 and cell-mediated cytotoxicity medi-
ted by Fas and perforin. The relative importance of
ach of these pathways may be organ dependent. Mu-
ine models suggest Fas/Fas ligand-mediated apopto-
is and cytotoxicity mediates GVHD in the liver
41,67].
ON-HLA IMMUNOGENETIC ASSOCIATIONS WITH GVHD
Numerous studies have examined the role of poly-
orphisms in immunoregulatory genes and transplanta-
ion outcome [23,24,41,68-109] (Table 2). Most have
xamined related, myeloablative, HLA-matched trans-
lants. Pro- and anti-inﬂammatory cytokine genes have
een most commonly studied, including TNF, IL1,
LRN (encoding the IL-1 receptor antagonist), IL2, IL6,
L10, and IFNG. Acute GVHD and mortality measure-
ents such as TRM, DFS, and overall survival are the
ost widely studied outcomes. There are much less data
vailable regarding cGVHD and non-GVHD trans-
lant-relatedmorbidities such as infection, noninfectious
ulmonary dysfunction, veno-occlusive disease, and mu-
ositis. Several studies have examined unrelated donor
ransplants [24,70,76,87,89], and 1 study has examined
BT [24]. Similarly, there are few data speciﬁcally ex-
mining the non-HLA genomics of nonmyeloablative
CT.
NF GENOMICS AND ALLO-HCT OUTCOME
Polymorphisms in the genes encoding the cyto-
ines TNF, IL-1, IL-6, IL-10, and IFN- have been qost consistently associated with outcomes such as
GVHD and mortality. TNF alleles were the ﬁrst
on-HLA variants reported to be associated with
VHD in sibling myeloablative allo-HCT [68]. Stud-
es of TNF genomics in allo-HCT illustrate several
mportant issues in non-HLA genomic studies that
arrant detailed discussion. The cytokine genes TNF
nd LTA (encoding lymphotoxin ) lie in the class III
egion of the MHC and are highly polymorphic (Fig-
re 2). TNF gene contains multiple single nucleotide
olymorphisms (SNPs) that have been studied in
any disease settings, including SNPs in the pro-
oter (eg, at nucleotides 1031, 863, 857, 376,
308, and 238 relative to the transcription start
ite), ﬁrst intron (488), and several microsatellite
olymorphisms named TNFa, TNFb, TNFc, TNFd,
nd TNFe. An association between the TNFd3 allele
nd aGVHD was the ﬁrst report of an association
etween cytokine genotype and allo-HCT outcome
68] and was conﬁrmed in subsequent cohorts and in
ultivariable analyses [69,110,111]. This suggests that
he TNFd3 association is biologically important and
otentially clinically useful; however, it should be
oted that the TNFd microsatellite lies approximately
0 kb distal to the TNF gene in intron 3 of the
eukocyte-speciﬁc transcript gene, LST1. From these
tudies, it is thus unclear if the TNFd polymorphism
irectly inﬂuences TNF secretion, and whether it is
he TNF variant most strongly linked with GVHD.
urther, this association has not been detected in
ubsequent studies [74,79,89].
Other studies have examined TNF SNPs that lie in
loser proximity to the TNF gene. The most widely
tudied TNF polymorphism is an SNP at position
308 in the TNF promoter, which has been associated
ith a diverse array of inﬂammatory, infectious, and
alignant diseases [112]. Associations between TNF
308 genotype and GVHD and organ toxicity have
een identiﬁed in small cohorts [80,81]; however,
ost studies, including several examining large or
ultiple cohorts and incorporating multivariable anal-
sis, have found no association with this polymor-
hism [23,68,74,79,83,89,90]. Several groups includ-
ng our own have investigated other SNPs in the TNF
ene. In a study of 2 cohorts of related myeloablative
ransplants (total n  160), we detected a strong as-
ociation between the intronic TNF 488A allele and
GVHD, higher grade GVHD, early mortality, and
GVHD [90]. Other investigators have reported asso-
iations between other TNF polymorphisms and allo-
CT outcome, including the 1031T/863C/
857C haplotype and high-grade aGVHD [76], and
he TNF a5, d4, and 1031C alleles with GVHD and
nferior survival [89,111].
The balance of evidence suggests that TNF vari-
nts are important risk factors for GVHD, but the
uestion remains as to which variant is most strongly
Table 2. Studies of Non-HLA Immunogenetic Variants and Outcome of Allo-HSCT‡
Study
Type of
Transplant, n Genetic Variants Examined
Genetic Variants
Associated with Outcome Association
Middleton et al [68] Sibling, 49 TNF d VNTR,308
IL101064 VNTR
TNF d3 homozygosity (R)
IL10 1064 1 allele length (R)
1 aGVHD III-IV
1 aGVHD III-IV
Cavet et al [69] Sibling, 144 TNF d VNTR
IL101064 VNTR,1082
TNF d 3/3 homozygous (R)
IL101064 1 allele length (R)
1 Mortality
1 aGVHD III-IV
Takahashi et al [70] Sibling, 49; URD, 13 TNF308
IL-10.G (CA)n VNTR
TNF308A (D)
IL-10.G 1 allele length (D)
1 aGVHD III-IV OR 29.4
1 cGVHD OR 4.5
Cavet et al [71] Sibling, 80 IFNG intron 1 (CA)n VNTR
IL6174, IL6 3= (AT) minisatellite
TNF d VNTR, IL101064 VNTR,1082, LTA
NcoI-AspIH, CTLA4 VNTR, TGFB1509
IFNG 3/3 (R)
IL6 174 G/G (R)
TNF d3/3 (R and D)
IL10 1064 (R)
1 aGVHD III-IV, OR 3.9
1 cGVHD, OR 4.25
1 aGVHD III-IV, OR 3.3
1 aGVHD, OR 4.6
Cullup et al [72] Sibling, 99 IL1B 511, 3953, IL1RN VNTR IL1RN*2 (D) 2 aGVHD III-IV
Lorenz et al [73] Sibling, 237 TLR4 codons 299, 399 None
Socie et al [74] Sibling, 100 TNF 308,238, d VNTR, LTA 252, IL6174,
IL101082,819,592, IFNG 874
IL10 GCC homozygosity (R and D)
IL6 (R)
1 aGVHD RR  3.5 (D), 7.9 (R)
1 cGVHD RR 4.2
Tambur et al [75] Pediatric sibling, 24 TNF 308, TGFB1 codons 10, 25, IL6 174, IL10
1082,819,592, IFNG 874
TGFB1 1 aGVHD
Hattori et al [41] Pediatric sibling, 67 IL4, IL4R, IL10, TGFB1, TGFB1RII, IFNG, IFNGR2,
and IRF1
TGFB1 codon 10 Pro
TGFB1RII 1167T
1 aGVHD OR 3.0
1 aGVHD OR 4.1
Ishikawa et al [76] URD, 462 TNF 1031,863,857 TNFRSF1B codon 196 TNF TCC haplotype
TNFRSF1B 196R (D)
1 aGVHD III-IV
2 Relapse 1 aGVHD III-IV
Kogler et al [24] Unrelated cord blood, 115 TNF d VNTR, IL101064 VNTR No associations
Middleton et al [77] Sibling, 88 VDR intron 8 BsmI and ApaI RFLPs VDR ApaI A (R)
VDR ApaI A (D)
1 aGVHD
2 Survival
Mullighan et al [78] Related, 96 MBL2550(H/L),221(X/Y), codons 52, 54, 57 MBL2 coding mutation (D)
MBL2 HYA haplotype (R)
1 Major infection
2 Major infection
Nordlander et al [79] URD, 111; sibling, 85 TNF308, TNFd VNTR, IL-101064 VNTR,
IL101082
TNFd*4 (sibling donors)
IL101082 b1 homozygosity (R) (URD)
IL101064*13 homozygosity (R)
1 aGVHD II-IV
1 aGVHD
1 aGVHD II-IV
Rocha et al [23] Sibling, 107 TNF308, TNFB 252, IL1RA VNTR, IL6174,
IL101084, FCGR2A, FCGR3A, FCGR3B
(HNA-1); MBL2 codons 52, 54, 57 MPO463;
ICAM1
FCGR2A 131R (R)
MPO 463A (D)
FCGR3B genotype (D)
IL1RN*2 absence (D)
IL10 GG (R), IL1RN (R)
Shorter time to first infection
Severe bacterial infection,
1 Day 180 mortality
Faster neutrophil recovery,
1 Day 180 mortality
1 aGVHD II-IV
1 cGVHD
Wang et al [80] Not stated, 49 TNF308,238 TNF308 (D) 1 aGVHD III-IV 1 Extensive cGVHD
Bogunia-Kubik et al [81] Sibling, 70 TNF308, LTA 249 (NcoI) TNF308 and LTA NcoI genotype Non-GVHD III-IV organ toxicity
Cullup et al [82] Sibling, 115 IL1A 889, IL1A VNTR, IL1B511, 3953,
IL1RN VNTR
IL1A889*2 (D), IL1A VNTR*2 (D) 1 cGVHD
Lin et al [83] Sibling, 993 IL1B 511 and 3954, IL1RN 9261, IL6174,
IL10 1082 and592, TNF308
IL10592A/A (R) 2 aGVHD III-IV, death in remission
MacMillan et al [108] URD, 95 IL2330 IL2330G (R) 1 aGVHD
MacMillan et al [84] URD, 90 IL1A 889, IL1B 511, IL1RN VNTR IL1A 889T (R and D)
IL1B 511T (R and D)
1 Survival, 1TRM
1 Survival
Middleton et al [85] Sibling, 108 ESR1 intron 1PvuII and XbaI RFLP, promoter
VNTR ESR2 intron 5 VNTR, 1082, 1730;
TNF d, IL10, IL6, IFNG, IL1RN, VDR
ESR1 intron 1 PX haplotype (R) 1 aGVHD 2 survival
Stark 2003 [86] Sibling, 104 TNFRSF1B codon 196; IL6174,
IL101082,819,592; IL1RN VNTR
TNFRSF1B 196R (R)
TNFRSF1B 196R (D)
1 aGVHD
1 cGVHD
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Table 2. Studies of Non-HLA Immunogenetic Variants and Outcome of Allo-HSCT‡ (continued)
Study
Type of
Transplant, n Genetic Variants Examined
Genetic Variants
Associated with Outcome Association
Cardoso et al [87] URD, 157 IL18137,607,656 IL18 GCG haplotype 2TRM and 1 survival
Holler et al [88] Sibling, 78; related, 4; URD, 87 CARD15 SNPs 8, 12, 13 CARD15 mutations (D, or R and D together) 1 aGVHD III-IV, gut aGVHD, TRM
Keen et al [89] URD, 182 TNF1031,308,238; TNFa, TNFd VNTRs;
IL10 VNTR,1082,819,592.
TNF a5, d4, TNF1031C
IL10 R2-GCC haplotype (D)
IL10 R3-GCC haplotype (D)
2 Survival
2 Survival
1 Survival
No associations with aGVHD.
Mullighan et al [90] Related, 160 TNF308,238, 488; IL1A889; IL1B511,
3953, IL1RN 11100, IL1R1 970, IFNG
5297, TNFRSF61377 and 670; MBL2
TNF 488A (D/R)
IL6174 (D)
IL10 ATA
TNFRSF6670G (R)
1 aGVHD, early death, 1 cGVHD
1 aGVHD
1 cGVHD
1 aGVHD, 1 major infection
Mlynarczewska
et al [91]
Sibling, 71 adult, 31 pediatric IFNG intron 1 VNTR, 874 SNP IFNG intron 1 non 2/2 genotypes 1 aGVHD II-IV
Pihusch et al [92] Related, 46, URD, 43 F5 1691, F2 20210A, MTHFR 677, ITGB3 a1/a2,
FGB 455, SERPINE1675, ACE In/del
SERPINE1675 4G/4G 1 Catheter thrombosis, VOD
Shaw et al [93] URD, 189 TNF 308,238 TNF 308A Delayed neutrophil engraftment
Srivastava et al [94] Pediatric thalassemic, 116 GSTM1, GSTT1 GSTM1 null genotype VOD
Bogunia-Kubik et al [95] 160 (49 pediatric, 85 NMSCT) IFNG intron 1 VNTR IFNG 3/3 (R) 1 aGVHD and 1 cGVHD
Bogunia-Kubik and
Lange [96]
133 (52 pediatric, 70
haploidentical/URD)
HSPA1L 2763 HSPA1L 2763 AA (R) 1 aGVHD
Bogunia-Kubik et al [97] 83 (15 pediatric, 34
haploidentical/URD)
IFNG intron 1 VNTR IFNG 3/3 (R) 1 aGVHD and EBV reactivation
Karabon et al [98] 93† IL6174; IL10 1082,819,592 IL10 GCC haplotype (R) and IL6174G (D) 1 aGVHD
Kesh et al [130] 127† TLR1, 2, 4, and 6 (multiple SNPs) TLR1 R80T TLR1 N248S  TLR6 S249P Invasive aspergillosis
Kim et al [99] Sibling, 60 IL10 1082,819,592 IL10 ATA haplotype 1 cGVHD
Lin et al [100] Sibling, 953 IL10RB 238, IL10,592 IL10 592A (R) and IL10RB c238G (D) 2 aGVHD III-IV
Onizuka et al [101] Sibling, 118 ACE intron 16 In/Del ACE D/D 1 NIPD
Seo et al [102] Related, 90; URD, 15 IL10 1082,819,592 IL10 non-ACC haplotype (R) Invasive pulmonary aspergillosis
Laguila Visentainer
et al [103]
Sibling, 118 TNF308, IL6174, IL101082,819,592,
IFNG874, TGFB1 869, 915
IL6 174 (R or D) 1 cGVHD
Chien et al [104] 572† BPI , TLR2-4,6, CD14, IL1B, IL1RN, IL6, IL6, LBP,
TIRAP, IRAK4, TRAF6 and TNF (69 SNPs)
4 BPI haplotypes (D and R) Airflow decline
Bettens et al [111] URD, 131 IL101082, IL1B511, IL4R3223 and1902
SNPs; TNFa,d, IL1RN, IL10 1064 VNTRs
TNF d3/d3, d4, d5 (R)
IL10 1064 (12,14,15) alleles (R)
2 Survival
2 Survival
Granell et al [109] T-depleted† CARD15 SNPs 8, 12, 13 CARD15 variants (R) 2 DFS
Holler et al [105] Sibling, 225 CARD15 SNPs 8, 12, 13 CARD15 variants (D or R) 1TRM, 1aGVHD III-IV
Shamim et al [106] Sibling, 120; URD, 75 IL7R 510, 1237, 2087, 3110 IL7R 1237G (D) 2 Survival, 1 TRM
Terakura et al [107] URD, 373 GSTM1 and GSTT1 deletions GSTM1 deletion 2 Survival, 1 TRM
1 indicates increased; 2, decreased; ACE, angiotensin I converting enzyme, BPI, bactericidal/permeability-increasing protein; D, donor; ESR1, estrogen receptor 1 (); ESR2, oestrogen receptor 2 (); FCGR2A, FCGR3A, FCGR3B, low affinity
receptor for Fc fragment of IgG, types IIa, IIIa and IIIb; F2. factor 2 (prothrombin); F5, factor V; FGB, fibrinogen ; GSTM1, glutathione S-transferase M1; GSTT1, glutathione S-transferase 1; HSPA1L, heat shock 70-kDa protein 1-like
(HSP70-HOM); IL, interleukin, eg, IL1RN, IL-1 receptor antagonist; IRAK, IL-1 receptor-associated kinase 4; IRF, IFN regulatory factor; LBP, LPS binding protein; LTA, gene encoding lymphotoxin  (also known as TNF); MBL2,
mannose-binding lectin; MPO, encoding myeloperoxidase; NIPD, noninfectious pulmonary dysfunction; NMSCT, nonmyeloablative SCT; R, recipient; RFLP, restriction fragment length polymorphism; SERPINE1, plasminogen activator
inhibitor 1; TGF, transforming growth factor; TIRAP, toll-interleukin 1 receptor (TIR) domain containing adaptor protein; TLR, Toll-like receptor; TNF, gene encoding tumour necrosis factor; TNFRSF1B, gene encoding TNF receptor 2;
TNFRSF6, gene encoding Fas (Apo-1); TRAF6, TNF receptor-associated factor 6; TRM, VDR, gene encoding vitamin D receptor; VNTR, variable number tandem repeats (microsatellite); VOD, hepatic veno-occlusive disease
*HLA 5-6/6 antigen match.
†Donor type not stated.
‡All studies listed examine HLA-matched myeloablative transplants unless otherwise stated. All polymorphisms are SNPs unless otherwise stated. Gene symbols are italicized and have been adapted where appropriate from the original
publications according to HUGO Gene Nomenclature Committee guidelines (http://www.gene.ucl.ac.uk/nomenclature/).
Genom
ics
of
Allogeneic
Stem
CellTransplantation
133
a
c
f
a

[
m
p
s
n
p
c
t
G
c
u
w
n
t
p
a
i
p
g
t
T
d
h
a
o
m
b
I
s
e
g
p
S
[
l
o
W
o
r
I
i
p
g
d
[
T
[
m
g
h
T
p
a
e
i
c
I
D
d
a
t
f
d
p
c
t
o
O
W
F
H
ﬂ
r black
C. G. Mullighan and P. G. Bardy134ssociated with GVHD, and would serve as the best
linical marker. To address this question, we per-
ormed extended genotyping of the TNF promoter
nd intronic SNPs (1031, 863, 857, 308,
238, and 488) in the cohort described previously
90] and a prospective cohort of sibling, HLA-
atched myeloablative and nonmyeloablative trans-
lants. This identiﬁed 9 TNF SNP haplotypes and
howed that the TNF 488A allele was in strong, but
ot absolute, linkage disequilibrium with the TNF
romoter 857T allele. TNF 857T, which lies in
loser proximity to the regulatory regions of TNF
han does 488A, was more strongly associated with
VHD than was 488A, and these associations were
onﬁrmed in the second cohort (Mullighan and Bardy,
npublished data). Importantly, these associations
ere observed in myeloablative allo-HCT but not in
onmyeloablative SCT. These observations illustrate
he importance of detailed genotyping of multiple
olymorphisms in candidate genes and careful char-
cterization of transplant variables such as condition-
ng intensity. Our study has also collected peritrans-
lant sera to examine associations between cytokine
enotype and blood levels and further clarify the func-
ional effects of the associated variants.
One additional important issue is the location of
NF within the HLA region and the strong linkage
isequilibrium across the region [93,113]. Compre-
ensive studies examining TNF SNPs, microsatellites,
nd HLA genotype will be important and may dem-
nstrate interaction among multiple TNF SNP and
icrosatellite alleles and allo-HCT outcome, as has
een demonstrated in other settings [114].
L10 GENOMICS AND ALLO-HCT OUTCOME
IL10 polymorphisms have also been extensively
tudied and merit discussion because they have been
xamined in the largest studies of non-HLA allo-HCT
enomics reported to date. The IL10 gene contains 2
igure 2. Genomic polymorphism of TNF. TNF and the adjacen
LA-DRB1 and TNF are separated by approximately 850 kb, and
anking SNPs and microsatellites (variable number tandem repeats
epresented by shaded boxes, and translated regions of the gene byromoter microsatellite polymorphisms and multiple iNPs. In one of the earliest studies, Middleton et al
68,69] reported associations between increased allele
ength at the IL10 -1064 microsatellite and risk/severity
f GVHD, a ﬁnding conﬁrmed by other groups [79].
e and others have detected associations between SNPs
r haplotypes of SNP alleles in the IL10 promoter and
isk of aGVHD and/or cGVHD [23,74,83,90,98,99].
L-10 is a pleiotropic cytokine that is frequently anti-
nﬂammatory and antagonizes the release or action of
roinﬂammatory TNF. One might expect that IL10
enotypes associated with reduced in vitro IL-10 pro-
uction, such as the 1082A/819T/592A haplotype
115], would be associated with increased risk of GVHD.
his was found in several studies cited previously
90,99]. However, in a study of 993 sibling HLA-
atched transplants, Lin et al [83] studied 5 cytokine
enes and detected an association between IL10 592A
omozygosity and protection from high-grade aGVHD.
his appears counterintuitive, because this genotype has
reviously been associated with reduced IL-10 levels,
nd thus the reverse association with GVHD might be
xpected. The investigators suggested that this genotype
s associated with increased IL-10 production in this
ontext, but most evidence regarding IL10 genotype and
L-10 levels suggests the opposite is true [115-118].
espite the size and power of this study, these contra-
ictory ﬁndings emphasize the need to replicate associ-
tions in independent cohorts from different centers and
o carefully examine associations between genotype and
unctional readouts, such as blood levels or in vitro pro-
uction, before incorporation into clinical tissue typing
rotocols. Lin et al [100] also recently reported an asso-
iation between donor IL-10 receptor  (IL10RB) geno-
ype and severe GVHD, although the functional effects
f this polymorphism have not been investigated.
THER NON-HLA IMMUNOGENETIC ASSOCIATIONS
ITH GVHD
Several other gene variants have been reproduc-
gene lie on the short arm of chromosome 6 separated by 1 kb.
nd HLA-B by 250 kb. Locations of commonly studied TNF and
own. TNFd and e microsatellites lie in the LST1 gene. Exons are
boxes. Arrows represent direction of transcription.t LTA
LTA a
) are shbly associated with GVHD, including polymor-
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Genomics of Allogeneic Stem Cell Transplantation 135hisms in the IL1 gene cluster [72,82,84], IL6
71,74,90,103], IFNG [71,91,95,97], and the TNFR
enes [76,86] (Table 2). The reader is referred to
ther reviews for additional discussion of these asso-
iations [119-121]. Recent studies have also examined
on-cytokine immunoregulatory gene polymorphisms
ncluding the estrogen and vitamin D receptor genes
nd the gene encoding the apoptosis molecule Fas
77,85,90]. Notable are reports of associations be-
ween polymorphisms in CARD15, which encodes
OD2, a molecule involved in the nuclear factor 	B
athway, and aGVHD and mortality in two mixed
ohorts of related and unrelated donor transplants
88,105]. CARD15 is a mediator of innate immunity in
he gut and is implicated in the pathogenesis of in-
ammatory bowel disease [122,123]. Moreover,
ARD15 variants were associated with gut GVHD,
nd the strength of association was inﬂuenced by the
ype of gut decontamination used. A recent report also
dentiﬁed associations between CARD15 genotype
nd DFS in HLA-matched, T cell-depleted allo-HCT
109]. This highlights the potential role of genetic
ariability in mediators of innate immunity in allo-
CT, as discussed below.
ENETIC DETERMINANTS OF OTHER COMPLICATIONS
FTER ALLO-HCT
Most studies of allo-HCT genomics have exam-
ned the risk of aGVHD and mortality. Fewer studies
ave investigated the genetic basis of other complica-
ions such as cGVHD and infection, two other leading
auses of morbidity and mortality. This is partly due
o the greater difﬁculty in accurately documenting,
haracterizing, and conﬁrming these more complex
nd longer-term outcomes. However, existing data
upport a role for cytokine polymorphisms and
GVHD risk [23,70,71,74,82,86,90]. It is important to
ote that one of the strongest risk factors for cGVHD
s prior aGVHD, and this potentially confounding
actor is frequently not addressed. This will be impor-
ant if genetic determinants unique to cGVHD patho-
enesis are to be identiﬁed.
Our group has actively pursued the question of
enetic predisposition to infection risk after allo-
CT. There is intense interest in the role of innate
mmune host defenses in clinical settings where adap-
ive immune responses (such as speciﬁc humoral re-
ponses and antigen-speciﬁc T cells) are compro-
ised, such as after allo-HCT [124]. Mannose-
inding lectin (MBL) is an innate host-defense
olecule that recognizes a diverse array of pathogens
ndependently of antibody and triggers activation of
he complement cascade [125]. The gene encoding
BL, MBL2, contains several common polymor-
hisms that profoundly inﬂuence circulating levels of ﬁomplement-ﬁxing MBL. Up to 40% of individuals
ave low circulating MBL levels [126], and reduced
BL levels are associated with a range of infective
iseases and complications when normal adaptive im-
unity is compromised [125]. There is intense inter-
st in MBL replacement therapy to prevent or treat
nfection in MBL-compromised individuals.
In a retrospective study of 96 myeloablative trans-
lantations [78], we detected associations between
BL2 genotype and risk of major infection after
ransplantation. MBL2 coding polymorphisms associ-
ted with low MBL levels were associated with a high
isk of major infection, and that MBL2 promoter vari-
nts that are associated with the highest blood levels of
BL are protective [78]. Subsequent studies have
etected associations between MBL2 genotype status
nd infection in autologous HCT [127,128], but data
n allo-HCT are conﬂicting [23,129]. Further, MBL is
n acute-phase reactant primarily synthesized by the
iver, and the effect of hepatotoxic conditioning regi-
ens on peritransplantation MBL levels is unclear.
To clarify the importance of MBL status in allo-
CT, we conducted a prospective study examining
BL2 genotype, blood MBL levels, and risk of major
nfection in myeloablative and nonmyeloablative allo-
CTs (Mullighan and Bardy, unpublished observa-
ions). This showed that pretransplantation MBL lev-
ls are higher in recipients than in their sibling
onors, reﬂecting an acute-phase response induced by
isease and prior treatment. Moreover, there was a
igniﬁcant increase in recipient MBL levels from base-
ine to day 14 after transplantation. This was most
vident in recipients lacking MBL2 coding mutations
nd receiving myeloablative TBI. An association be-
ween major infection and MBL status, as assessed by
BL2 genotype or MBL levels, was detected but was
ritically dependent on transplant type. A signiﬁcant
nteraction was observed between recipient MBL2
oding mutations and myeloablative TBI. For exam-
le, 70.6% of recipients with a coding MBL2 mutation
eceiving TBI developed major sepsis compared with
0% of those without mutations not receiving TBI.
o association between MBL status and infection was
etected in nonmyeloablative transplantations. These
esults suggest that MBL replacement therapy may be
eneﬁcial in MBL-deﬁcient individuals receiving TBI
onditioned transplants and further emphasize the im-
ortance of conﬁrmatory studies in well-characterized
ohorts.
Several other studies highlight the relevance of the
enomics of innate immunity in allo-HCT. MPO
myeloperoxidase) and Ig receptor gene variants have
een associated with infection [23], TLR (toll-like re-
eptor) variants with invasive aspergillosis [130], and
FNG variants with EBV reactivation [97]. Recently, a
creen of a number of innate immunity genes identi-
ed haplotypes in the bactericidal/permeability-in-
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C. G. Mullighan and P. G. Bardy136reasing protein BPI as risk factors for pulmonary
ysfunction and airﬂow decline after transplantation
104].
HARMACOGENOMIC DETERMINANTS OF ALLO-HCT
UTCOME
Toxicities of cytoreductive and immunosuppres-
ive agents such as methotrexate and busulfan are
mportant causes of morbidities such as mucositis,
elayed engraftment, and hepatic dysfunction, which
n turn may inﬂuence risks of GVHD and infection.
harmacogenomic approaches are increasingly used
o predict risk of complications and guide individual-
zed dosing [131,132]. Several groups have used tar-
eted busulfan dosing based on individualized phar-
acokinetic measurements to reduce toxicity and
ptimize engraftment [133-135].
Pharmacogenomic approaches examine the rela-
ion among polymorphisms in drug-metabolizing en-
ymes, drug pharmacokinetics, tumor response, and
reatment toxicity. For example, polymorphisms in
he TPMT gene encoding thiopurine methyltrans-
erase are associated with myelosuppression and re-
ponse to treatment in patients receiving 6-mercapto-
urine and azathioprine [136]. Polymorphisms in
ther drug-metabolizing enzymes such as cytochrome
450 enzymes, glutathione-S-transferases, and meth-
lenetetrahydrofolate reductase (MTHFR) have been
ssociated with drug response and toxicity and even
umor susceptibility in patients with cancer [131,136].
Pharmacogenomic factors also inﬂuence allo-
CT outcome. Methotrexate is widely used as an
mmunosuppressive drug for GVHD prophylaxis in
llo-HCT. MTHFR is a critical regulatory enzyme in
olate metabolism, and methotrexate metabolites in-
uence MTHFR activity. Two missense MTHFR
NPs, C677T and A1298C, inﬂuence MTHFR activ-
ty [137,138]. Ulrich et al [139] examined a MTHFR
77 SNP in allo-HCT patients receiving methotrex-
te and found that the MTHFR 677TT genotype,
ssociated with lower enzyme activity, was associated
ith increased mucositis and delayed platelet engraft-
ent [139]. This group has conﬁrmed these ﬁndings
nd also detected an association between combined
THFR 677 and 1298 genotypes and risk relapse of
ML after transplantation [140-142]. A smaller study
ound no associations between MTHFR genotype and
ucositis or engraftment [143]. Two recent studies
ave detected associations betweenMTHFR 677T and
hymidylate synthase (TS) genotypes and reduced risk
f GVHD, possibly due to the greater sensitivity to
ethotrexate associated with these alleles [144,145].
Veno-occlusive disease is a less frequent compli-
ation but commonly treatment refractory and fatal.
rugs used in pretransplantation conditioning such as musulfan contribute to the risk of veno-occlusive dis-
ase. Glutathione-S-transferases are involved in
usulfan metabolism, and a recent study of pediatric
atients undergoing allo-HCT for thalassemia ob-
erved associations among GSTM1 null genotype
which results in reduced GSTM1 activity), elevated
evels of busulfan metabolites, and veno-occlusive dis-
ase. These results of MTHFR and GSTM1 genotype
uggest that pharmacogenetic factors are important
eterminants of drug toxicity and clinical outcome in
llo-HCT.
K CELLS AND ALLO-HCT
The potential for NK cell alloreactivity to mediate
VL effects without severe GVHD in HLA-mis-
atched transplants has stimulated intense interest in
K biology in allo-HCT [146,147]. NK cells are
arge granular lymphocytes capable of causing lysis of
nfected or malignant cells in vitro. NK cells recognize
elf MHC class I molecules through activating and
nhibitory KIRs. NK autoreactivity is normally pre-
ented by inhibitory interactions between MHC class
molecules and inhibitory KIR. The KIR gene locus
ontains 15 genes on chromosome 19, and KIR diver-
ity arises from the number of genes on each KIR
aplotype, the combination of maternal and paternal
aplotypes, and allelic polymorphism.
Missing Self” and NK Alloreactivity
The interaction between KIR and HLA class I is a
ey determinant of NK alloreactivity and can, in part,
e predicted by the HLA class I type of donor and
ecipient. The inhibitory KIR2DL1 receptor recog-
izes group 2 HLA-Cw alleles with asparagine at
odon 77 and lysine at codon 80 of HLA-Cw, and
IR2DL2/3 recognizes group 1 alleles (serine 77,
sparagine 80).
The importance of this “missing self” model of
K alloreactivity in allo-HCT was ﬁrst appreciated in
aploidentical transplants (haplo-HCT), in which do-
or and recipient are mismatched for 1 HLA haplo-
ype. Such transplantations increase the number of
vailable donors, but generally require intensive im-
unosuppression or T cell depletion to avoid graft
ejection and severe GVHD. In a study of T-depleted
nrelated haplo-HCT, NK alloreactivity in the GVH
irection, as predicted by HLA-Cw typing, was asso-
iated with low rates of graft rejection, and disease
elapse and mortality were observed in transplants for
ML, but not for ALL [148]. This was accompanied
y low rates of GVHD, attributed to NK-mediated
epletion of recipient APCs [148]. The researchers
onﬁrmed these striking results in a larger cohort of
atients with AML [149], suggesting that NK ligand
atching could be used to select haploidentical or
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Genomics of Allogeneic Stem Cell Transplantation 137LA-mismatched unrelated donors. Although some
enters have adopted this practice, other studies have
ielded conﬂicting data, with one study ﬁnding a sur-
ival advantage for KIR ligand incompatibility [149],
ut others showing no effect or trends toward in-
reased GVHD and lower survival in those with GVH
K alloreactivity [150-154]. Notably, a recent multi-
enter retrospective study of 1571 HLA-matched and
ismatched, predominantly T-replete unrelated do-
or transplants found no beneﬁcial effect of KIR li-
and incompatibility upon relapse or mortality. These
iscrepant results may be explained by the high cell
ose, T depletion, and lack of post-transplantation
mmunosuppression used by Ruggeri et al [148], par-
icularly as residual T cells in the graft may adversely
ffect T cell reconstitution [155].
Missing Ligand” and NK Alloreactivity
The “missing self” model described above is in-
ufﬁcient to predict NK alloreactivity in all situations,
uch as in HLA-matched transplants. Because the KIR
enes at 19q13 segregate independently from HLA at
p21, individuals may express inhibitory KIR but no
orresponding HLA ligand and, conversely, HLA li-
ands but no corresponding KIR. It is thought that
ost individuals possess a complete complement of
nhibitory KIR [156,157], but the frequency of class I
igand expression is highly variable. In a small study,
his missing ligand model was a better predictor of
utcome than was KIR ligand incompatibility in
aplo-HCT [158], and a study of 178 HLA-matched
ibling allo-HCT found that missing KIR ligand was
ommon (63%) and associated with reduced relapse
nd improved survival [159]. A multicenter retrospec-
ive analysis of 1770 myeloablative T-replete HLA-
atched and -mismatched allo-HCTs found that
LA homozygosity predicting missing KIR ligand
as associated with reduced relapse in AML, ALL,
nd CML [160].
Further, these models do not consider activating
IR gene complement and polymorphism [147],
hich in combination with KIR ligand genotype has
able 3. Potential Clinical Integration of Non-HLA Genomic Data in
Potential Application
efine donor selection Cytokine ge
KIR/KIR lig
odify conditioning Pharmacog
Avoid TBI
odify immunosuppression Modify met
Intensify im
ovel therapies to prevent GVHD Cytokine b
ovel therapies to prevent infection MBL replac
doptive immunotherapy to promote GVL Engineered
Ex vivo expeen reported to inﬂuence survival in sibling HLA- eatched allo-HCT [161]. Two recent reports also
uggested that donor-activating KIR genotype inﬂu-
nces the risk of CMV reactivation after allo-HCT
162,163].
How might prediction of NK alloreactivity be
sed clinically? Recent large retrospective studies have
uggested that selection of HLA-mismatched donors
ased on predicting “missing self” alone is unrealistic,
t least outside the high cell dose, T-deplete haplo-
CT setting described by Ruggeri et al [148]. These
arger studies suggest that consideration of missing
IR ligand is important in HLA-matched and -mis-
atched allo-HCT [160,164]. Modeling of NK allo-
eactivity may also require consideration of activating
IR genotype, although larger prospective studies
enotyping KIR in addition to HLA are required.
NCORPORATING NON-HLA GENOMIC DATA INTO
LINICAL TRANSPLANTATION PRACTICE: PROMISE
ND PITFALLS
The studies discussed above describe numerous
on-HLA immunogenetic variants that appear to in-
uence allo-HCT outcome and may prove useful clin-
cal markers to assist patient counseling, donor selec-
ion, tailoring of immunosuppressive therapy, and
dentiﬁcation of novel therapeutic targets. Examples
f these strategies are listed in Table 3, but important
uestions remain. Which associations may be deemed
onclusive, and for genes consistently associated with
utcome such as TNF or IL10, which markers are
ost appropriate? We suggest that few, if any, non-
LA markers are ready for routine clinical use with-
ut further studies that address the limitations of ex-
sting data. The chief of these is sample size and the
eed for conﬁrmation. Many studies are small and
linically heterogeneous, examine only a small num-
er of genes/polymorphisms, and are underpowered
o perform the multivariable analyses necessary to
etermine primacy of association. There is also an
rgent need to examine unrelated donor and nonmy-
SCT
Example
s that predict severe GHVD (eg, TNF, IL6, IL10, IFNG, CARD15)
otyping
data, eg, busulfan dose according to GSTM1 genotype
-deficient recipients
ate dose according to MTHFR (and folate pathway) genotype
uppression in those at highest risk of GVHD
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C. G. Mullighan and P. G. Bardy138ive sources of stem cells such as umbilical cord blood.
e suggest the following priorities for future studies.
Conﬁrmation of associations in large cohorts. It is im-
ortant to comprehensively genotype genes repeat-
dly associated with outcome such as TNF, IL10, IL6,
FNG, and MBL in large cohorts. It is important that
enotyping of all putatively functional polymorphisms
n each gene and genotyping multiple genes are per-
ormed. Even the largest studies to date have geno-
yped relatively few genes and polymorphisms [83].
uch comprehensive genotyping is important to de-
ermine the strongest association within a gene, to
xamine interaction between variants, and to examine
ssociations with functional readouts. Very few cen-
ers will have sufﬁciently large cohorts, and carefully
urated repositories of DNA with comprehensive clin-
cal will be invaluable [165]. It is likely that these
tudies can realistically only be performed in a collab-
rative fashion, and we and others are involved in such
rojects.
Correlation of genotype with phenotype. Determining
he functional effect of associated polymorphisms re-
ains an important challenge, as shown by the asso-
iations between IL10 genotype and GVHD. Al-
hough many studies have examined cytokine
enotype or levels and allo-HCT outcome, few have
ssessed both. Even for widely studied genes such as
NF, data examining the functional effects of poly-
orphisms are limited and conﬂicting [43,112,166],
nd there are very few data regarding the variants
eproducibly associated with GVHD, TNF 488A and
3 [167,168]. These data are derived from nontrans-
lantation settings, and it is possible that the biologic
ffects of each cytokine and polymorphism are context
ependent. Our studies of MBL status and infection
how that there remains a role for smaller studies that
arefully correlate genetic and functional measure-
ents with allo-HCT outcome. Prospective studies
hat collect comprehensive genotypic data and exam-
ne changes in encoded mediators in the peritrans-
lantation period (such as blood cytokine levels or in
itro cytokine production) and clinical outcome will
e important.
Risk prediction. The ultimate goal of these studies is
o construct a clinically useful model of risk that in-
orporates clinical and genetic information to improve
isk prediction and aid clinical decision making. It is
onceptually attractive that a single genetic variant
ight be used to assist clinical decision making, but
his is likely overly simplistic in practice, especially in
he HLA-matched setting, in which additional genetic
ariables may further shrink the donor pool. A more
easible approach will be the construction of a risk
index” of clinical and genetic variables that not only
istinguishes multiple potential donors but also high-
ights recipients at highest risk of complications for shom alternative therapies should be considered.
his will entail large studies of multiple test and val-
dation cohorts, and these collaborative efforts, such as
hose of the International HLA and Immunogenetics
orkshop [169], are in progress.
UTURE DIRECTIONS
In addition to conﬁrming and clarifying existing
mmunogenetic associations, systematic discovery of
ew associations will be important in the ﬁeld of
llo-HCT genomics. Completion of the Human Ge-
ome Project, the cataloging of 1 million SNPs by
he HapMap project [170], and the advent of high-
hroughput, genome-wide, and targeted genotyping
echnologies are transforming the practice of genetic
isease-association studies. Allo-HCT genomics is no
xception. Most existing studies have used relatively
aborious strategies to genotype small numbers of can-
idate genes and polymorphisms. Several technologies
re currently available to genotype hundreds of thou-
ands of SNPs [171] in a nonselective, genome-wide
ashion or targeting known genes and pathways at
igh resolution. Studies examining associations of
500 000 SNPs with GVHD in a large Japanese
llo-HCT cohort are in progress [172]. Further, these
enome-wide approaches have identiﬁed a novel type
f polymorphism, genomic copy number variation, at
xceptionally high resolution, the signiﬁcance of
hich is unclear in most clinical contexts, including
llo-HCT [173].
Together these studies promise to provide de-
ailed and comprehensive information regarding the
enomic basis of allo-HCT outcome. Unifying this
nformation and integrating with functional and clin-
cal markers will pose a major challenge, but one that
ill be met with enthusiasm by the allo-HCT com-
unity.
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